Prediction of Delayed Toxic Cardiomyopathy in Children (SpeckleAnthra2)
Longitudinal Analysis of Myocardial Function by Speckle Tracking Echocardiography and Prediction of Delayed Toxic Cardiomyopathy Associated With Anthracycline Therapy in Children
Sponsor: University Hospital, Montpellier
Terminated
Analyses will be performed with data from included patients until the end of the inclusion period. The clinical team did not wish to extend the inclusion period in order not to delay the analyses.
Other terminated trials from University Hospital, Montpellier
Other Cardiotoxicity trials with similar outcome
This NA trial investigates Cardiotoxicity and Childhood Cancer and is currently terminated or withdrawn. University Hospital, Montpellier leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
4 versions recorded-
Mar 2025 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Apr 2023 — Jul 2024 [monthly]
Recruiting NA
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Montpellier
For direct contact, visit the study record on ClinicalTrials.gov .